RxDoctor Payments Data

Ira Robinson, MD

Internal Medicine · Stockbridge, GANPI 1174615116

Payments from drug & device makers

$12,497in general payments, 2019–2025

Across 762 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$863
  • Kowa Pharmaceuticals America, Inc.$833
  • AbbVie$794
  • plus $6K from 50 others

What the payments were for

  • Food & beverage$12,33799%
  • Education$1601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC94$1,384
AstraZeneca78$1,361
Novo Nordisk106$1,185
Pfizer48$863
Kowa Pharmaceuticals America, Inc.52$833
AbbVie(2 entities)44$794
Amarin Pharma, Inc.45$777
Bayer29$469
Astellas Pharma US Inc22$421
Amgen(2 entities)19$403
GSK16$294
Daiichi Sankyo Inc.16$293
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$251
Boehringer Ingelheim12$220
Xeris Pharmaceuticals, Inc.11$212
Abbott12$195
Insulet Corporation13$174
Biohaven Pharmaceuticals, Inc.9$156
Idorsia Pharmaceuticals US Inc7$152
Ironwood Pharmaceuticals, Inc9$151
Otsuka America Pharmaceutical, Inc.6$147
Sanofi-aventis U.S. LLC9$143
Corcept Therapeutics5$125
Exact Sciences6$112
Novartis6$112
Vanda Pharmaceuticals Inc.5$111
Biohaven Pharmaceutical Holding Company Ltd.5$96
Currax Pharmaceuticals LLC6$95
Teva Pharmaceuticals USA, Inc.6$94
Supernus Pharmaceuticals, Inc.5$89
Takeda Pharmaceuticals U.S.A., Inc.5$85
Johnson & Johnson5$67
Dexcom, Inc.3$61
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$60
Sumitomo Pharma America, Inc.2$49
Eisai Inc.3$46
Merck3$42
Lundbeck LLC2$33
Mylan Specialty L.p.2$32
Atland Pharmaceuticals, LLC1$32
Cequr Corporation1$25
Actelion Pharmaceuticals US, Inc.1$24
Axsome Therapeutics, Inc.1$24
Paratek Pharmaceuticals, Inc.1$22
Gilead1$20
Kaleo, Inc.1$19
Almatica Pharma LLC1$19
Athena Bioscience, LLC1$18
Clarus Therapeutics Inc.1$15
Valinor Pharma, LLC1$15
Sanofi Pasteur Inc.1$15
Senseonics, Incorporated1$14
Arbor Pharmaceuticals, Inc.1$14
Genentech USA, Inc.1$13
E.r. Squibb & Sons, L.L.C.1$12
Impel Pharmaceuticals Inc.1$12

How this compares

$12,497 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$113,434
Medicare patients
325
Services billed
1,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide317$482,429
OzempicSemaglutide183$294,060
RybelsusSemaglutide66$118,607
FarxigaDapagliflozin Propanediol46$62,905
JardianceEmpagliflozin54$62,604
EliquisApixaban41$47,313
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$44,906
VascepaIcosapent Ethyl50$38,739
LinzessLinaclotide25$35,513
TrulicityDulaglutide17$29,642
Nurtec OdtRimegepant Sulfate13$27,568
XareltoRivaroxaban17$22,976
MovantikNaloxegol Oxalate25$21,948
Tresiba Flextouch U-100Insulin Degludec19$21,597
MyrbetriqMirabegron14$15,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,384$512,071334 claims
Novo NordiskOzempic, Rybelsus$1,185$412,666249 claims
PfizerEliquis, Nurtec Odt$863$74,88054 claims
AstraZenecaFarxiga$1,361$62,90546 claims
Boehringer IngelheimJardiance$220$62,60454 claims
GSKTrelegy Ellipta$294$44,90633 claims
AbbVieLinzess$794$35,51325 claims
Johnson & JohnsonXarelto$67$22,97617 claims
Astellas Pharma US IncMyrbetriq$421$15,18414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →